Orphan drug uttroside B impedes MASH progression and HCC development in experimental models.

ABSTRACT:

Background & aims

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by excessive accumulation of fat, accompanied by inflammation and liver injury, ultimately triggering chronic conditions, including fibrosis and cirrhosis, which may progress to hepatocellular carcinoma (HCC). Uttroside B (Utt-B), a phytosaponin isolated in our lab, has gained global recognition owing to its anti-HCC potential and is currently a United States FDA-designated 'orphan drug' against HCC. The present study highlights Utt-B as a propitious candidate drug against MASH and MASH-induced HCC.

Methods

MASH and MASH-induced HCC were developed in C57BL/6J mice using two distinct murine models: a high-fat diet model and a streptozotocin-induced steatohepatitis-derived HCC model, fol

SUBMITTER: Rayginia TP 

PROVIDER: S-EPMC12857343 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature